Scarica l'app Stockscreener
1.29
8.40%
0.10
Pre-mercato:
1.33
0.04
+3.10%
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Gain Therapeutics Stock Price Forecast. Should You Buy GANX? - StockInvest.us
Coya Therapeutics, Inc. (COYA) stock price, news, quote and history - Yahoo Finance UK
Coya Therapeutics, Inc. (COYA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Coya Therapeutics, Inc. (COYA) stock price, news, quote and history - Yahoo Finance Singapore
Gain Therapeutics, Inc. (NASDAQ:GANX) Stock Has Average Price Target of $7.50 - MarketBeat
Form 8K Gain Therapeutics Inc For: 1 October By Investing.com - Investing.com India
Form 8K Gain Therapeutics Inc For: 1 October By Investing.com - Investing.com Canada
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders - GlobeNewswire Inc.
Long-term data on a Parkinson’s drug candidate will be presented in Seoul. - Stock Titan
Form 8K Gain Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 8K Gain Therapeutics Inc For: 28 September By Investing.com - Investing.com UK
Form 8K Gain Therapeutics Inc For: 28 September By Investing.com - Investing.com Canada
Gain Therapeutics Inc (NASDAQ: GANX) Share Price, GANX Stock News, GANX Share Price & Updates - kalkine.ca
Xenon Pharmaceuticals Q2 2026 Earnings: Narrower-Than-Expected Loss Supports Modest Stock GainEarnings Quality Analysis - careplusvn.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy - Investing.com
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
Gain (GANX) Financial Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; After Results: The Stock Gains 1.97% on the DayEarnings Surprise Stocks - vinanet.vn
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT) - The Globe and Mail
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Charm Flow - vinanet.vn
GSA Capital Partners LLP Purchases Shares of 632,131 Gain Therapeutics, Inc. $GANX - MarketBeat
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Put Flow Alert - dars.gov.et
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Common Gap - dars.gov.et
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Wyckoff Spring - www.dars.gov.et
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
BTIG Research Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX) - MarketBeat
Gain Therapeutics, Inc. Q2 2026: Net loss $4.7M, EPS $(0.11) — 10-Q Summary - TradingView
Gain Therapeutics (GANX) faces going-concern risk while advancing Parkinson’s drug - Stock Titan
Gain Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gain Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Gain Therapeutics Q2 Results: EPS Beats Estimates, Loss Narrows - scanx.trade
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall - TradingView
Gain Therapeutics 2Q Loss/Shr 11c >GANX - Moomoo
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update - Yahoo Finance
Gain Therapeutics (GANX) Advances 2% as Support at $1.72 HoldsRetracement Entry - dars.gov.et
Gain Therapeutics (GANX) Advances 2% as Support at $1.72 HoldsWeak Sell Signals - dars.gov.et
Gain Therapeutics Inc (GANX) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - finance.yahoo.com
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
0.68%
3.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):